Seelos Therapeutics (SEEL) Stock Price, News & Analysis

Company Overview

Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorders; SLS-005, a protein stabilizer for the treatment of amyotrophic lateral sclerosis and Sanfilippo syndrome; and SLS-006, a partial dopamine agonist for the treatment of patients with Parkinson's disease (PD). Its preclinical programs include SLS-007, a peptidic inhibitor to treat patients with PD; SLS-008 for the treatment of pediatric indications; SLS-004 for the treatment of PD; SLS-010, an H3 receptor antagonist; and SLS-012. The company was founded in 2016 and is headquartered in New York, New York.

Key Stats

• Today's Range: $0.90 to $1.20
• 50-Day Range: $0.92 to $5.41
• 52-Week Range: $0.82 to $713.47
• Volume: 10,909 shs
• Average Volume: 181,339 shs
• Market Capitalization: $340,400.00
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

SEEL Stock Analysis - Frequently Asked Questions

How have SEEL shares performed this year?

Seelos Therapeutics' stock was trading at $177.92 at the start of the year. Since then, SEEL stock has decreased by 99.5% and is now trading at $0.92.
View the best growth stocks for 2024 here.

How were Seelos Therapeutics' earnings last quarter?

Seelos Therapeutics, Inc. (NASDAQ:SEEL) announced its earnings results on Wednesday, August, 14th. The company reported $1.92 earnings per share (EPS) for the quarter. The company earned $0.38 million during the quarter.

When did Seelos Therapeutics' stock split?

Seelos Therapeutics shares reverse split before market open on Friday, September 27th 2024. The 1-16 reverse split was announced on Wednesday, September 25th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, September 26th 2024. An investor that had 100 shares of stock prior to the reverse split would have 6 shares after the split.

Who are Seelos Therapeutics' major shareholders?

Seelos Therapeutics' top institutional investors include Modera Wealth Management LLC (0.50%).
View institutional ownership trends.

How do I buy shares of Seelos Therapeutics?

Shares of SEEL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Seelos Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Seelos Therapeutics investors own include Block (SQ), Digital Turbine (APPS), Palantir Technologies (PLTR), Okta (OKTA), CrowdStrike (CRWD), SoFi Technologies (SOFI) and ChargePoint (CHPT).

Company Calendar

• Last Earnings: 8/14/2024
• Today: 11/04/2024
• Next Earnings (Estimated): 11/12/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:SEEL
• CUSIP: N/A
• CIK: 1017491
• Web: www.seelostherapeutics.com
• Phone: (646) 293-2100
• Fax: 858-436-8155
• Employees: 20
• Year Founded: 2016

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-37,880,000.00
• Net Margins: 203.13%
• Pretax Margin: 203.13%
• Return on Equity: N/A
• Return on Assets: -431.47%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.08
• Quick Ratio: 0.08

Sales & Book Value

• Annual Sales: $2.20 million
• Price / Sales: 0.19
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($437.92) per share
• Price / Book: 0.00

Miscellaneous

• Outstanding Shares: 370,000
• Free Float: 368,000
• Market Cap: $410,700.00
• Optionable: Optionable
• Beta: 1.95